That Pricey New Alzheimer's Drug? Still Not Great

The video discusses a new Alzheimer's drug approved by the FDA, highlighting its ability to reduce brain plaques but questioning its impact on disease progression. The drug's high cost and potential side effects have sparked debate, leading to Medicare's cautious coverage approach, only for clinical trial patients. The controversy includes Biogen's dealings with the FDA and the economic burden on Medicare and Medicaid. The video emphasizes the need for effective treatments and the implications of limited access to the drug.

How does the cost of the Alzheimer's drug affect access for patients?

What is the current status of Medicare's coverage for the Alzheimer's drug?